Payment overview · 2025
General Payments
$1,652.81
91 reported records · 24 companies
Healthcare provider profile · identity verified
Emily D Hanson, DO
Allopathic & Osteopathic Physicians|Family Medicine · MURPHYSBORO, IL · NPI 1023083748
Verified facts
What the public records show
CMS Open Payments records show Emily D Hanson, DO received $1,652.81 in general payments during 2025 across 91 reported records.
ABBVIE INC. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $265.40 | 16.1% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $233.03 | 14.1% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $201.63 | 12.2% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $178.19 | 10.8% | 11 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $98.01 | 5.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.59 | 4.5% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.57 | 4.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.24 | 3.5% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $54.20 | 3.3% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $50.73 | 3.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.45 | 3.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $49.31 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.87 | 2.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $37.70 | 2.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.11 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.85 | 2.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.05 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.36 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.19 | 1.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.85 | 1.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.21 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.87 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.85 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.55 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,652.81 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $201.63 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $201.63 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $200.75 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $199.01 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $119.85 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $98.01 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $89.46 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $65.57 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $58.34 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $58.34 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.74 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.24 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.24 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $54.20 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.45 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $49.31 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.87 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.87 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.18 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.60 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.11 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.62 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $12.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 119 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 31 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 603 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 135 |
| Lisinopril | Lisinopril | 405 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 122 |
| Gabapentin | Gabapentin | 329 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 75 |
| Alprazolam | Alprazolam | 214 | 46 |
| Metformin Hcl | Metformin Hcl | 204 | 58 |
| Omeprazole | Omeprazole | 198 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 39 |
| Furosemide | Furosemide | 191 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 49 |
| Lorazepam | Lorazepam | 172 | 36 |
| Carvedilol | Carvedilol | 169 | 47 |
| Meloxicam | Meloxicam | 163 | 49 |
| Potassium Chloride | Potassium Chloride | 154 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 37 |
| Simvastatin | Simvastatin | 134 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 44 |
| Pregabalin | Pregabalin | 130 | 21 |
| Eliquis | Apixaban | 128 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 33 |
| Jardiance | Empagliflozin | 119 | 27 |
| Losartan Potassium | Losartan Potassium | 115 | 39 |
| Montelukast Sodium | Montelukast Sodium | 110 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 34 |
| Sertraline Hcl | Sertraline Hcl | 105 | 34 |
| Allopurinol | Allopurinol | 100 | 27 |
| Tramadol Hcl | Tramadol Hcl | 99 | 25 |
| Ozempic | Semaglutide | 96 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 32 |
| Prednisone | Prednisone | 93 | 62 |
| Buspirone Hcl | Buspirone Hcl | 92 | 24 |
| Trulicity | Dulaglutide | 88 | 14 |
| Trazodone Hcl | Trazodone Hcl | 87 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 20 |
| Spironolactone | Spironolactone | 62 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 60 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 15 |
| Clonazepam | Clonazepam | 58 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 14 |
| Methylprednisolone | Methylprednisolone | 52 | 41 |
| Mirtazapine | Mirtazapine | 52 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 14 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Celecoxib | Celecoxib | 42 | 19 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 13 |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Famotidine | Famotidine | 40 | 13 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Baclofen | Baclofen | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Metformin Hcl Er | Metformin Hcl | 38 | 12 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Glipizide | Glipizide | 35 | 12 |
| Atenolol | Atenolol | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 30 |
| Valsartan | Valsartan | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 23 |
| Nystatin | Nystatin | 33 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 23 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | 11 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Bupropion Xl | Bupropion Hcl | 28 | 11 |
| Estradiol | Estradiol | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 13 |
| Metronidazole | Metronidazole | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Topiramate | Topiramate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Cephalexin | Cephalexin | 19 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,652.81 · 91 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BEXSERO, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, INGREZZA, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, Tymlos, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error